Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1998 Dec 7;11(2):94–103. doi: 10.1002/(SICI)1098-2825(1997)11:2<94::AID-JCLA5>3.0.CO;2-K

Distribution of radiolabelled anti‐CA125 monoclonal antibody OC125‐F(ab′)2‐fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients

Martina M Uttenreuther‐Fischer 1,2, Herbert Feistel 3, Friedrich Wolf 3, Wolfram Jäger 2,✉
PMCID: PMC6760690  PMID: 9058243

Abstract

Ovarian cancer is a highly malignant tumor of mainly postmenopausal women. The long‐term prognosis of this malignancy is largely determined by micrometastasis present at the time of second‐look surgery. In general, patients face a poor outcome. New radio‐immunoscintigraphic methods to target tumor tissue specifically via antigen‐antibody binding were developed. However, few studies so far investigated the pattern of in vivo distribution of radiolabelled mAbs and/or the specificity of antigen‐antibody interaction. In this study we examined the immunological interaction and distribution of 131 I‐OC125‐F(ab′)2‐fragment, an anti‐CA‐125 mAb, in patients with CA‐125 positive ovarian malignancies. Sixteen patients with primarily CA‐125 positive gynecological tumors underwent REGAJ surgery. Biopsies of tumor tissue and not tumor infiltrated tissue, serum, and ascites were sampled during or prior to REGAJ surgery, respectively. After preparation of tissue cytosols, samples were assessed for CA‐125 and radioactive uptake. By radiochromatography immunological analysis for presence of the target antigen CA‐125, the mAb 131I‐OC125‐F(9ab′)2‐fragment, and immune complexes was performed on different specimen. CA‐125 concentrations were higher in serum samples, ascites, and malignant tissue biopsies of malignoma patients compared to those without signs of malignant disease. CA‐125 was higher in the tissue cytosol than in the cell membrane fraction. Gel filtration revealed CA‐125 with moieties of 75,000 to < 600,000 d. Accumulation of radioactivity was more frequently associated with the presence of unbound 131I‐OC125‐F(ab′)2‐fragment or high molecular weight immune complexes. Radioactive uptake, however, was not confined to tissue of high CA‐125 expression. Moreover, both immune complex as well as 131I‐OC125‐F(ab′)2‐fragment could be isolated from cytosols of tissue not infiltrated by tumor cells as well. Our study demonstrates that the majority of CA‐125 is located intracellularly and thus inaccessible to 131I‐OC125‐F(ab′)2‐fragment per se. The uptake of 131I‐OC125‐F(ab′)2‐fragment into the cytosol of tumor‐free and malignant tissue samples prompts us to speculate that certain mechanisms for antigen‐specific and nonspecific cellular trafficking of mAbs do exist. We present a model to explain our observations. J. Clin. Lab. Anal. 11:94–103. © 1997 Wiley‐Liss, Inc.

Keywords: ovarian cancer, REGAJ, TAA CA‐125, mAb OC125‐F(ab′)2‐fragment, antibody distribution

References

  • 1. Piver MS, Baker TR, Piedmonte M, Sandecki AM: Epidemiology and etiology of ovarian cancer. Sem Oncol 18: 177–185, 1991. [PubMed] [Google Scholar]
  • 2. Pfleiderer A: Maligne Tumoren der Ovarien. Bücherei des Frauenarztes, Band 23 Martius G, ed. Ferdinand Enke Verlag, Stuttgart, 1976. [Google Scholar]
  • 3. Ovarian cancer and older women : Is treatment less aggressive. J Natl Cancer Inst 84: 6–7, 1992. [DOI] [PubMed] [Google Scholar]
  • 4. Larson SM: Radioimmunology. Cancer 67: 1253–1260, 1991. [DOI] [PubMed] [Google Scholar]
  • 5. Mach JP, Buchegger F, Forni M, Ritschard J, Berche C, Lumbroso JD, Schreyer M, Girardet C, Accolla RC, Carrel S: Use of radiolabeled monoclonal anti‐CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 2: 239–249, 1981. [DOI] [PubMed] [Google Scholar]
  • 6. Goldenberg DM, De Land F, Kim E, Bennett S, Primus FJ, Van Nagell JR, Jr. , Estes N, De Simones P, Rayburn P: Use of radiolabeled antibodies to carcinoembryonic antigen for detection and localization of diverse cancers by external photoscanning. N Engl J Med 298: 1384–1388, 1978. [DOI] [PubMed] [Google Scholar]
  • 7. Jäger W, Feistel H, Paterok EM, Ronay G, Tulusan AH, Wolf F, Lang N: Resection guided by antibodies (REGAJ): a diagnostic procedure during second‐look operation in ovarian cancer patients. Br J Cancer 62, Suppl. X: 18–20, 1990. [PMC free article] [PubMed] [Google Scholar]
  • 8. Pateisky N, Philipp K, Sevelda P, Skodler WD, Enzelsberger H, Hamilton G, Burchell J, Schatten C: Radioimmunoscintigraphy using monoclonal antibodies before second‐look surgery in patients suffering from ovarian cancer. Gynecol Obstet Invest 24: 212–216, 1987. [PubMed] [Google Scholar]
  • 9. Rao GS, Hanjani P: Detection of human ovarian tumor‐associated antigens by antibodies isolated from ovarian carcinoma ascitic fluid. Am J Obstet Gynecol 159: 94–98, 1988. [DOI] [PubMed] [Google Scholar]
  • 10. Steward JSW, Hird V, Snook D, Sullivan M, Hooker G, Courtenay‐Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE, Munro AJ, Epenetos AA: Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of I‐131 labeled monoclonal antibodies. I J Radiation Oncology 16: 405–413, 1989. [DOI] [PubMed] [Google Scholar]
  • 11. Crombach G, Scharl A, Würz H: CA 125 in normal tissue and carcinomas of the uterine cervix, endometrium and fallopian tube. Arch Gynecol Obstet 244: 113–122, 1989. [DOI] [PubMed] [Google Scholar]
  • 12. Haisma HJ, Moseley KR, Battaile A, Griffiths TC, Knapp RC: Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC125 after intravenous and intraperitoneal administration in gynecologic tumors. Am J Obstet Gynecol 159: 843–848, 1988. [DOI] [PubMed] [Google Scholar]
  • 13. Fuith LC, Daxenbichler G, Dapunt O: CA 125 in the serum and tissue of patients with gynecological disease. Arch Gynecol Obstet 241: 157–164, 1987. [DOI] [PubMed] [Google Scholar]
  • 14. Catt KJ, Durfan ML: Isolation and properties of gonadotropin receptors. In — 1960, p 171–200.
  • 15. Darnell J, Lodish H, Baltimore D: The study of cell organization and subcellular structure In Molecular Cell Biology. Darnell JE, ed. Scientific American Books, New York, 1990, p 109–150. [Google Scholar]
  • 16. DDV Diagnostika: Doppelliganden‐(J‐125 und H‐3)‐Kit zur Simultan‐Messung von Estradiol‐ und Progesteron‐Rezeptoren. DDV‐Diagnostika 1–14, 1988.
  • 17. Hjelmeland LM: Solubilization of native membrane proteins. Methods Enzymol 182: 253–264, 1990. [DOI] [PubMed] [Google Scholar]
  • 18. Klug TL, Bast RC Jr., Niloff JM, Knapp RC, Zurawski VR, Jr. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44: 1048–1053, 1984. [PubMed] [Google Scholar]
  • 19. Harlozinska A, Bar JK, Gawlikowski W, Richter R, Cislo M: CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms. Ann Chir Gynaecol 80: 368–375, 1991. [PubMed] [Google Scholar]
  • 20. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, Jo J, Ballesta AM: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 37: 1379–1383, 1991. [PubMed] [Google Scholar]
  • 21. Mojiminiyi OA, Bramwell ME, Kennedy SH, Shepstone BJ, Humm SM, Barlow DH: Immunoreactive determinants of CA 125 in women with endometriosis. J Clin Pathol 42: 1272–1275, 1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Schwartz PE, Chambers SK, Chambers JT, Tilton K, Foemmel R: CA 125 in peritoneal washings and fluid: Correlation with plasma CA 125 and peritoneal cytology. Obstet Gynecol 73: 339–342, 1989. [PubMed] [Google Scholar]
  • 23. Papadimitriou A, Baziotis N, Zissimopoulos A, Efremidis A, Kandylis K, Frangaki C, Politi D: Elevated pleural CA 125 levels in patients with benign and malignant effusions: Correlation with CA 15‐3 levels. Eur J Nucl Med 16: 492, 1990. (Abstract). [Google Scholar]
  • 24. Mezger J, Permanetter W, Gerbes AL, Wilmanns W, Lamerz R: Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol 41: 633–643, 1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Mezger J, Haussinger KE, Wilmanns W, Lamerz R: ×High Ca 125 serum level in benign ascites or pleural effusion× Hohe CA‐125‐Serum‐Spiegel bei benignem Aszites oder Pleuraerguss. Geburtshilfe und Frauenheilkunde 47: 463–465, 1987. [DOI] [PubMed] [Google Scholar]
  • 26. Mezger J, Wilmanns W, Lamerz R: Elevated serum CA 125 levels in patients with benign ascitic or pleural effusions. Tumour Biol 9: 47–52, 1988. [DOI] [PubMed] [Google Scholar]
  • 27. Bast RC, Jr. , Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883–887, 1983. [DOI] [PubMed] [Google Scholar]
  • 28. Pharmacia : Gel filtration calibration kit instructional manual for protein molecular weight determinations by gel filtration. Pharmacia Laboratory Separation and Pharmacia AB, eds. Pharmacia, Piscataway, Uppsala, 1985. [Google Scholar]
  • 29. Pharmacia : Gel filtration Principles and Methods. Pharmacia LKB Biotechnology , ed. Rahms, Lund, Sweden, 1991. [Google Scholar]
  • 30. Cooper T: Gel permeation chromatography In The Tools of Biochemistry. Wiley & Sons, New York, 1977, p 169–193. [Google Scholar]
  • 31. Fischer L: Laboratory techniques in biochemistry and molecular biology In Gel filtration Chromatography. Work TS, Burdon RH, eds. Elsevier/North, Holland, 1980. [Google Scholar]
  • 32. Johnstone A, Thorpe R: Immunochemistry in Practice. Blackwell, Oxford, 1987. [Google Scholar]
  • 33. Stellwagen E: Gel filtration. Methods Enzymol 182: 317–328, 1990. [DOI] [PubMed] [Google Scholar]
  • 34. Haisma HJ, Battaile A, Stradtman EW, Knapp RC, Zurawski VR, Jr. Antibody‐antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer. Int J Cancer 40: 758–762, 1987. [DOI] [PubMed] [Google Scholar]
  • 35. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH: Phase I trial of the murine monoclonal anti‐GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52: 4342–4347, 1992. [PubMed] [Google Scholar]
  • 36. de los Frailes MT, Stark S, Jaeger W, Hoerauf A, Wildt L: Purification and characterization of the CA 125 tumor‐associated antigen from human ascites. Tumour Biol 14: 18–29, 1993. [DOI] [PubMed] [Google Scholar]
  • 37. Bast RC Jr., Knapp RC: The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma In Important Advances in Oncology. DeVita VT, Jr., Hellman S, Rosenberg SA, eds. Lippincott, Philadelphia, 1987, p 39–50. [PubMed] [Google Scholar]
  • 38. Jacobs I, Bast RC, Jr. The CA 125 tumour‐associated antigen: A review of the literature. Human Reprod 4: 1–12, 1989. [DOI] [PubMed] [Google Scholar]
  • 39. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497, 1975. [DOI] [PubMed] [Google Scholar]
  • 40. Cohen AM, Martin EW, Jr. , Lavery I, Daly J, Sardi A, Aitken D, Bland K, Mojzisik C, Hinkle G: Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 126: 349–352, 1991. [DOI] [PubMed] [Google Scholar]
  • 41. Hinkle GH, Mojzisik CM, Loesch JA, Hill TL, Thurston MO, Sampsel J, Olsen J, Martin EW, Jr. The evolution of the radioimmunoguided surgery system: an innovative technique for the intraoperative detection of tumor. Antibody Immunoconjugates Radiopharmaceuticals 4: 339–358, 1991. [Google Scholar]
  • 42. Fleuren GJ, Nap M, Aalders JG, Trimbos JB, de Bruijn HWA: Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors. Cancer 60: 2437–2442, 1987. [DOI] [PubMed] [Google Scholar]
  • 43. Ruibal A, Encabo G, Martinez‐Miralles E, Murcia C, Capdevila JA, Salgado A, Martinez‐Vasquez JM: CA 125 seric levels in nonmalignant pathologies. Bull Cancer 71: 145–148, 1984. [PubMed] [Google Scholar]
  • 44. Beatty JD, Beatty BG, O'Conner‐Tressel M, Do T, Paxton RJ: Mechanisms of tissue uptake and metabolism of radiolabeled antibody—role of antigen: antibody complex formation. Cancer Res 50: 840s–845s, 1990. [PubMed] [Google Scholar]
  • 45. Simpson‐Herren L, Noker PE, Wagoner SD: Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity. Cancer Chemother Pharmacol 22: 131–136, 1988. [DOI] [PubMed] [Google Scholar]
  • 46. Watanabe Y, Endo K, Koizumi M, Kawamura Y, Saga T, Sakahara H, Kuroki M, Matsuoka Y, Konishi J: Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice. Cancer Res 49: 2884–2889, 1989. [PubMed] [Google Scholar]
  • 47. Fischer P, Baum RP, Tauber M, Boeckmann W, Weier S, Scherberich JE: Immunoscintigraphic localization of renal tumours in an extracorporeal perfusion model with a monoclonal antibody against gammaglutamyltransferase. Cancer Immunol Immunother 35: 283–288, 1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Uttenreuther‐Fischer MM, Huang CS, Yu AL: Pharmacokinetics of human mouse chimeric anti‐GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 41: 331–338, 1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Uttenreuther‐Fischer MM, Huang CS, Reisfeld RA, Yu AL: Pharmacokinetics of anti‐ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother 41: 29–36, 1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Boerman OC, Sharkey RM, Blumenthal RD, Aninipot RL, Goldenberg DM: The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int J Cancer 51: 470–475, 1992. [DOI] [PubMed] [Google Scholar]
  • 51. Duewell S, Horst W, Westera G: Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co‐112) xenografted in the nude mouse. Dependence on tumor size and injected dose. Cancer Immunol Immunother 23: 101–106, 1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM: Influence of animal host and tumor implantation site on radio‐antibody uptake in the GW‐39 human colonic cancer xenograft. Int J Cancer 44: 1041–1047, 1989. [DOI] [PubMed] [Google Scholar]
  • 53. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ: The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 52: 835–842, 1992. [PubMed] [Google Scholar]
  • 54. Schmid SL: The mechanism of receptor‐mediated endocytosis: More questions than answers. Bio Essays 14: 589–596, 1992. [DOI] [PubMed] [Google Scholar]
  • 55. Wawrzynczak EJ: Systemic immunotoxin therapy of cancer: Advances and prospects. Br J Cancer 64: 624–630, 1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Novokhofer I, Amstutz HP, Macke HR, Schwarzbach R, Zimmermann K, Morgenthaler JJ, Schubiger PA: Cellular processing of copper‐67‐labeled monoclonal antibody chCE7 by human neuroblastoma cells. Cancer Res 55: 46–50, 1995. [PubMed] [Google Scholar]
  • 57. Martell LA, Agrawal A, Ross DA, Muraszko KM: Efficacy of transferrin receptor‐targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53: 1348–1353, 1993. [PubMed] [Google Scholar]
  • 58. Jäckle S, Runquist EA, Miranda‐Brady S, Havel RJ: Trafficking of the epidermal growth factor receptor and transferrin in three hepatocytic endosomal fractions. J Biol Chem 266: 1396–1402, 1991. [PubMed] [Google Scholar]
  • 59. Warren G, Woodman P, Pypaert M, Smythe E: Cell‐free assay and the mechanism of receptor‐mediated endocytosis. Trends Biochem Sci 13: 462–465, 1988. [DOI] [PubMed] [Google Scholar]
  • 60. Mauri D, Wysscoray T, Brander C, Pichler WJ: Improved sensitization of antigen‐presenting cells with transferrin‐bound peptides: Advantages in competition for antigen presentation. Cell Immunol 158: 59–70, 1994. [DOI] [PubMed] [Google Scholar]
  • 61. Helin K, Beguinot L: Internalization and down‐regulation of the human epidermal growth factor receptor are regulated by the carboxyl‐terminal tyrosines. J Biol Chem 266: 8363–8368, 1991. [PubMed] [Google Scholar]
  • 62. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB: Processing of antibody‐radioisotope conjugates after binding to the surface of tumor cells. Cancer 73: 787–793, 1994. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES